Eli Lilly acquires Orna Therapeutics in deal worth up to 2.4 billion dollars
Eli Lilly announced today that it will acquire Orna Therapeutics for up to $2.4 billion in cash. The deal expands the company's therapy development pipeline.
Insights:
Eli Lilly and Company announced today, February 9, that it will acquire therapy developer Orna Therapeutics for up to $2.4 billion in cash. This major corporate acquisition will result in the transfer of ownership of Orna to Lilly, representing a material transaction with direct financial implications for both the buyer and the target.
